Monday 24 Jun, 2024 12:44 PM
Site map | Locate Us | Login
   Vardhman Holdings Ltd leads gainers in 'B' group    Sanghvi Movers edges higher after bagging work orders worth Rs 180 crore    BSE SME United Cotfab make a decent listing    NSE SME GP Eco Solutions India rallies on debut    Bombay Burmah Trading Corporation Ltd leads gainers in 'A' group    NBCC secures order worth Rs 100 crore    L&T arm bags significant order to build solar and energy storage plant    Ujjivan SFB slumps after trimming FY25 loan growth guidance by 500 bps    Volumes jump at Bajaj Holdings & Investment Ltd counter    Hero MotoCorp hikes prices of motorcycles and scooters    Lupin gains on receiving EIR from USFDA for New Jersey facility    MAS Financial gains on raising Rs 500 crore via QIP    Welspun Specialty spurts after emerging as L1 bidder for thermal power project    Capital Goods shares gain    Consumer Durables shares rise 
Saravan Stocks
Hot Pursuit
Scrips, which has significant changes during the market hours.
Sun Pharma Q4 PAT rises 34% YoY to Rs 2,656 cr
22-May-24   16:23 Hrs IST

Revenue from operations grew by 10.14% to Rs 11,813.33 crore in Q4 FY24 as against Rs 10,725.57 crore recorded in Q4 FY23.

Profit before exceptional items and tax was at Rs 2,917.16 crore, registering a growth of 21% on YoY basis. The company reported an exceptional item of Rs 101.64 crore during the period under review.

During the quarter, EBITDA (including other operating revenues) grew 8.3% year on year to Rs 3,035.2 crore. EBITDA margin was at 25.3% in Q4 FY24 as against 25.6% posted in Q4 FY23.

India formulations sales were at Rs 3,707.8 crore for Q4FY24, up 10.2% YoY and accounted for 31.4% of total consolidated sales for the quarter.

US formulation sales were $476 million for Q4 FY24, recording a growth of 10.9% over Q4 FY23 and accounted for about 33.5% of total consolidated sales for the quarter.

Taro posted Q4FY24 sales of $165 million, up by 12.5%. Excluding the impact of GTN adjustments, sales growth was high-single digit. Net profit for Q4FY24 was $15.1 million.

Formulation sales in Emerging Markets were $245 million for Q4 FY24, registering a growth of 10.8% over Q4 last year and accounted for about 17.2% of total consolidated sales for the quarter.

Formulation sales of rest of the world (RoW) market sales were $196 million during the quarter, up 2.5% YoY and accounted for approximately 13.8% of total consolidated sales for the quarter.

For Q4 FY24, external sales of API were at Rs 415.80 crore for Q4FY24, rising 2.7% YoY. The company said that it continues to focus on increasing API supply for captive consumption for key products.

Consolidated R&D investment for Q4FY24 was at Rs 900 crore as compared to Rs 665.70 crore for Q4 last year.

On full year basis, the company's consolidated net profit rose 13.01% to Rs 9576.38 crore on 10.35% increase in revenue to Rs 47,758.45 crore in FY24 over FY23.

Dilip Shanghvi, chairman and managing director, said, ?During FY24, two of our businesses surpassed USD 1 billion in annual sales, namely global specialty and emerging markets. This achievement of critical mass in key markets is a testimony to several years of hard work put in by respective teams. We shall continue to build our specialty portfolio and invest further to gain scale across our businesses.?

Meanwhile, the board has recommended a final dividend of Rs 5 per equity share for the financial year 2023-24, subject to approval of shareholders.

Further, the board has also approved the appointment of Dilip Shanghvi, managing director of the company, as the chairman of the board with immediate effect.

Sun Pharmaceuticals Industries is a leading global pharmaceutical company with specialty and generic presence and India's top pharma company.

The scrip declined 1.95% to end at Rs 211.55 on the BSE.

Powered by Capital Market - Live News

   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID:       Customers grievances :     Compliance officer : Mr.R Udayakumar ,,  Mobile No: 7305522205
Hit Count : 33425977
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 56990 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. SSPL WEALTH Pvt. Ltd